Treatment Approaches for Omalizumab-Refractory Chronic Spontaneous Urticaria
Luis Felipe Ensina, Marta Ferrer, Mona Al-Ahmad, Daria Fomina, Emek Kocatürk, Mojca Bizjak-Suran · 2026
Read Treatment Approaches for Omalizumab-Refractory Chronic Spontaneous Urticaria by Luis Felipe Ensina, Marta Ferrer, Mona Al-Ahmad, Daria Fomina, Emek Kocatürk, Mojca Bizjak-Suran (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13289661.txt.
Description
Luis Felipe Ensina and colleagues review a 2026 set of options for chronic spontaneous urticaria that resists omalizumab. Urticaria means recurring itchy hives driven by mast cells, harming quality of life. Omalizumab helps many who fail high-dose antihistamines, yet some respond partly or not at all, and sorting true resistance from missed diagnosis matters first.
Validated scores over seven days and control tests should judge response, the authors advise. Blood markers can hint at subtype: high IgE favors allergy-driven disease with better drug response, while low IgE and autoimmune signs favor a harder subtype. Cyclosporine remains a proven next step. Newer targeted drugs, including dupilumab and kinase blockers, are widening choices toward tailored care.
Catalog record
| CREATOR | Luis Felipe Ensina, Marta Ferrer, Mona Al-Ahmad, Daria Fomina, Emek Kocatürk, Mojca Bizjak-Suran |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 57805 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |